<< Back To Search

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This study is testing if a mix of three drugs can help people with a type of cancer called multiple myeloma. They will use lower amounts of the drugs to try to prevent bad side effects. The lower amounts of these drugs have not been officially approved yet.
*Third Opinion AI Generated Synopsis

Trial Summary
This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide and dexamethasone, has not been approved by the Food and Drug Administration (FDA) for the treatment of newly diagnosed MM.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?